David E. I. Pyott David E. I. Pyott, former Chairman and CEO of Allergan, Inc., was appointed to Tarsus Pharmaceuticals' Board of Directors. IRVINE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced the appointment of David E. I. Pyott, a distinguished leader in the global biopharmaceutical industry and former Chairman and CEO of Allergan, Inc., to its Board of Directors. “David is one of the most accomplished leaders in eye care, with a strong track r ...

Core Insights - Alcon is showcasing innovative technologies and presenting new study findings at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Copenhagen from September 12-15, 2025 [1][2] Product Innovations - Alcon is highlighting its latest innovations available in Europe, including the UNITY Vitreoretinal Cataract System (VCS), Clareon Vivity intraocular lens (IOL), and Voyager Direct Selective Laser Trabeculoplasty (DSLT) [2][5] - The Clareon Vivity IOL is noted as the most implanted extended depth of focus (EDOF) IOL worldwide, designed to deliver presbyopia correction [5] - Voyager DSLT is the first and only device of its kind, aimed at simplifying selective laser trabeculoplasty and enhancing patient experience [5] Clinical Evidence - More than 40 studies will be presented at the conference, demonstrating the benefits of Alcon technologies across various procedures including cataract, refractive, vitreoretinal, and glaucoma [6] - New data on Vivity IOLs indicate positive outcomes and patient satisfaction, particularly in special populations with co-morbidities [7] - Studies show reduced breakthrough pain medication use and less patient discomfort when performing cataract surgery at more physiologic intraocular pressure (IOP) [4][7] Symposium and Activities - Alcon will host a symposium focused on optimizing cataract surgery with near physiologic IOP, featuring expert faculty [8] - Additional symposium sessions and live surgery presentations will showcase Alcon's advanced technologies and their applications [10] Company Overview - Alcon is a global leader in eye care, with revenues of $9.8 billion and a net income of $1.5 billion in 2024 [18][23] - The company has a broad portfolio of products that enhance sight and improve lives, impacting over 260 million people annually [15]